Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from KalVista Pharmaceuticals ( (KALV) ).
On September 29, 2025, KalVista Pharmaceuticals completed the sale of $143.75 million in Convertible Senior Notes due 2031, including an additional $18.75 million purchased by initial buyers. The proceeds, estimated at $139 million after expenses, are intended for working capital, general corporate purposes, and the commercialization of EKTERLY. The notes, bearing an interest rate of 3.250% per annum, are senior unsecured obligations with specific terms for conversion and redemption, impacting the company’s financial strategy and market positioning.
The most recent analyst rating on (KALV) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on KalVista Pharmaceuticals stock, see the KALV Stock Forecast page.
Spark’s Take on KALV Stock
According to Spark, TipRanks’ AI Analyst, KALV is a Neutral.
KalVista Pharmaceuticals exhibits substantial financial challenges with weak revenue generation and profitability. While technical indicators show mixed momentum, the company’s strategic agreement with Kaken Pharmaceutical provides a potential growth avenue. However, the negative P/E ratio and lack of dividend yield negatively impact valuation. Overall, the stock’s score reflects financial struggles counterbalanced by strategic opportunities.
To see Spark’s full report on KALV stock, click here.
More about KalVista Pharmaceuticals
KalVista Pharmaceuticals operates in the pharmaceutical industry, focusing on the development and commercialization of small molecule protease inhibitors. The company is dedicated to advancing treatments for diseases with significant unmet needs, particularly in the area of hereditary angioedema.
Average Trading Volume: 1,303,672
Technical Sentiment Signal: Hold
Current Market Cap: $626.5M
For a thorough assessment of KALV stock, go to TipRanks’ Stock Analysis page.